Minerva Neurosciences (NERV)

• Market cap: $188M
• 1 day: 6.88%
• 5 days: -0.23%
• 1 month: 6.36%
• 3 months: -3.97%
• 6 months: 107.14%
• Year to date: 10.97%
• 1 year: 83.54%
• 5 years: -83.11%
• 10 years: -89.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 8